Drug repurposing against antibiotic resistant bacterial pathogens.

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Multidrug-resistance (MDR) and extensively drug-resistance (XDR) bacterial pathogens present a critical global health threat.
• Traditional antibiotic development faces significant challenges, necessitating innovative therapeutic strategies.
• Drug repurposing provides a promising avenue by identifying new uses for existing, FDA-approved drugs.

Purpose of the Study:

• To explore the potential of repurposing FDA-approved drugs against clinically relevant bacterial pathogens, including ESKAPE organisms.
• To identify suitable drug candidates, elucidate their mechanisms of action, and assess combination therapy potential.
• To review clinical trials and patent protection for repurposed antimicrobial drugs.

Main Methods:

• Literature review of existing FDA-approved drugs with potential antimicrobial activity.
• Analysis of mechanisms of action against target pathogens.
• Examination of clinical trial data and patent landscapes for repurposed drugs.

Main Results:

• Identification of several FDA-approved drugs with demonstrated efficacy against MDR/XDR pathogens.
• Elucidation of diverse mechanisms of action, including novel targets.
• Assessment of synergistic effects in combination therapies.

Conclusions:

• Drug repurposing is a viable and accelerated strategy to combat antimicrobial resistance.
• Repurposed drugs offer a faster route to new antimicrobial therapies with established safety profiles.
• Further research and clinical trials are essential to fully realize the potential of drug repurposing in infectious disease treatment.